Continuation Wedge (Bullish)
|Bid||0.00 x 800|
|Ask||10.48 x 1400|
|Day's Range||10.02 - 10.41|
|52 Week Range||7.91 - 14.10|
|Beta (5Y Monthly)||1.37|
|PE Ratio (TTM)||19.20|
|Earnings Date||Jul 28, 2020 - Aug 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.17|
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.
Shares of AbbVie Inc. were up 0.2% in premarket trading on Wednesday after the drugmaker and Ironwood Pharmaceuticals Inc. said a mid-stage study testing an experimental drug in patients with a form of irritable bowel disease (IBS) had failed. Ironwood's stock tumbled 12.4% before the market opened. The companies said they are halting development of the drug, as result of the Phase 2 clinical trial, which found there was no clinically meaningful effect on bowel function. "We are disappointed by the results from this study," Ironwood CEO Mark Mallon said in a news release. Year-to-date, AbbVie's stock is up 2.4%, Ironwood's shares are down 12.1%, and the S&P 500 has declined 7.4%.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D). The Phase II trial did not meet its primary or key secondary endpoints. Based on these findings, Ironwood and AbbVie plan to discontinue the development of MD-7246.
H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on Ironwood Pharma (NASDAQ:IRWD) on Monday, setting a price target of $11, which is approximately 7.95% above the present share price of $10.19.
Ladies and gentlemen, thank you for standing by, and welcome to the Ironwood Pharmaceuticals' First Quarter 2020 Investor Update Conference Call. The COVID-19 pandemic has caused substantial disruption to our lives, the healthcare system and the economy.
Ironwood (IRWD) delivered earnings and revenue surprises of -63.64% and -7.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its first quarter 2020 results and recent business performance, as well as an update related to the impact of the COVID-19 pandemic on its business.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for patent applications covering the formulation of the 72 mcg dose of LINZESS® (linaclotide) and methods of using the formulation. The patent applications are expected to issue in 2020 and expire in 2031.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2020 investor update conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, May 6, 2020. Individuals interested in participating in the call should dial (866) 393-4306 (U.S. and Canada) or (734) 385-2616 (international) using conference ID number 5494696. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Ironwood...
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today provided an update on certain impacts of COVID-19 on its business and the actions it is taking to mitigate the spread of this virus and help protect the safety and well-being of its employees, healthcare providers, patients and broader communities.
Ironwood (IRWD) delivered earnings and revenue surprises of 36.36% and 15.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
If you're interested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), then you might want to consider its beta (a...
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.